Deborah Stocken
A5023057149- Pancreatic and Hepatic Oncology Research
- Pancreatitis Pathology and Treatment
- Neuroendocrine Tumor Research Advances
- Psoriasis: Treatment and Pathogenesis
- Cardiac, Anesthesia and Surgical Outcomes
- Statistical Methods in Clinical Trials
- Liver Disease Diagnosis and Treatment
- Dermatology and Skin Diseases
- Health Systems, Economic Evaluations, Quality of Life
- Cancer Genomics and Diagnostics
- Gallbladder and Bile Duct Disorders
- Liver Diseases and Immunity
- Renal cell carcinoma treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Diabetes Management and Research
- Obstructive Sleep Apnea Research
- HER2/EGFR in Cancer Research
- Cervical and Thoracic Myelopathy
- Spine and Intervertebral Disc Pathology
- Enhanced Recovery After Surgery
- Gastroesophageal reflux and treatments
- Pediatric Hepatobiliary Diseases and Treatments
- Liver Disease and Transplantation
- Colorectal Cancer Surgical Treatments
- Breast Cancer Treatment Studies
University of Leeds
2017-2025
Newcastle University
2013-2021
MRC Clinical Trials Unit at UCL
2020
Weatherford College
2020
National Institute for Health Research
2014-2020
Versus Arthritis
2020
University Hospitals Birmingham NHS Foundation Trust
2020
NIHR Birmingham Biomedical Research Centre
2020
Newcastle upon Tyne Hospital
2020
Medical Research Council
2020
The effect of adjuvant treatment on survival in pancreatic cancer is unclear. We report the final results European Study Group for Pancreatic Cancer 1 Trial and update interim results.In a multicenter trial using two-by-two factorial design, we randomly assigned 73 patients with resected ductal adenocarcinoma to chemoradiotherapy alone (20 Gy over two-week period plus fluorouracil), 75 chemotherapy (fluorouracil), 72 both chemotherapy, 69 observation.The analysis was based 237 deaths among...
Adjuvant fluorouracil has been shown to be of benefit for patients with resected pancreatic cancer. Gemcitabine is known the most effective agent in advanced disease as well an cancer.To determine whether or gemcitabine superior terms overall survival adjuvant treatment following resection cancer.The European Study Group Pancreatic Cancer (ESPAC)-3 trial, open-label, phase 3, randomized controlled trial conducted 159 cancer centers Europe, Australasia, Japan, and Canada. Included ESPAC-3...
Both gemcitabine (GEM) and fluoropyrimidines are valuable treatment for advanced pancreatic cancer. This open-label study was designed to compare the overall survival (OS) of patients randomly assigned GEM alone or plus capecitabine (GEM-CAP).Patients with previously untreated histologically cytologically proven locally metastatic carcinoma pancreas a performance status <or= 2 were recruited. Patients GEM-CAP. The primary outcome measure survival. Meta-analysis published studies also...
To assess the influence of resection margins on survival for patients with resected pancreatic cancer treated within context adjuvant European Study Group Pancreatic Cancer-1 (ESPAC-1) study.Pancreatic is associated a poor long-term rate only 10% to 15% after resection. Patients positive microscopic (R1) have worse survival, but it not known how they fare in studies.ESPAC-1, largest randomized study resectable ever performed, set out look at roles chemoradiation and chemotherapy....
We undertook a comprehensive analysis of circulating myeloid-derived suppressor cells (MDSCs) and T regulatory (Tregs) in pancreatic, esophageal gastric cancer patients investigated whether MDSCs are an independent prognostic factor for survival. evaluated series plasma cytokines particular re-evaluated the Th2 cytokine interleukin-13 (IL-13). Peripheral blood was collected from 131 (46 60 25 gastric) 54 healthy controls. PBMC were harvested with subsequent flow cytometric MDSC (HLADR(-)...
BackgroundTransarterial chemoembolisation (TACE) is the standard of care for patients with intermediate stage hepatocellular carcinoma, while multikinase inhibitor sorafenib improves survival in advanced disease. We aimed to determine whether TACE progression-free versus placebo.MethodsWe did a multicentre, randomised, placebo-controlled, phase 3 trial (TACE 2) 20 hospitals UK unresectable, liver-confined carcinoma. Patients were eligible if they at least aged 18 years, had Eastern...
Purpose Adjuvant chemotherapy improves patient survival rates after resection for pancreatic adenocarcinoma, but the optimal duration and time to initiate is unknown. Patients Methods with ductal adenocarcinoma treated within international, phase III, European Study Group Pancreatic Cancer–3 (version 2) study were included if they had been randomly assigned chemotherapy. Overall analysis was performed on an intention-to-treat basis, retaining patients in their randomized groups, adjusting...
<h3>Importance</h3> While guidance on statistical principles for clinical trials exists, there is an absence of covering the required content analysis plans (SAPs) to support transparency and reproducibility. <h3>Objective</h3> To develop recommendations a minimum set items that should be addressed in SAPs trials, developed with input from statisticians, previous guideline authors, journal editors, regulators, funders. <h3>Design</h3> Funders regulators (n = 39) randomized were contacted...
OBJECTIVE To determine whether impaired awareness of hypoglycemia (IAH) can be improved and severe (SH) prevented in type 1 diabetes, we compared an insulin pump (continuous subcutaneous infusion [CSII]) with multiple daily injections (MDIs) adjuvant real-time continuous glucose monitoring (RT) conventional self-monitoring blood (SMBG). RESEARCH DESIGN AND METHODS A 24-week 2 × factorial randomized controlled trial adults diabetes IAH was conducted. All received comparable education,...
4006 Background: Despite improvements in multidisciplinary management, BTC has a poor outcome. Approximately 20% of cases are suitable for surgical resection with 5 year survival < 10%. BILCAP aimed to determine whether capecitabine (Cape) improves overall (OS) compared observation (Obs) following radical surgery. Methods: Patients completely-resected cholangiocarcinoma (CCA) or gallbladder cancer (including liver and pancreatic resection, as appropriate), adequate biliary drainage, no...
PURPOSE The BILCAP study described a modest benefit for capecitabine as adjuvant therapy curatively resected biliary tract cancer (BTC), and has become the standard of care. We present long-term data novel exploratory subgroup analyses. METHODS This randomized, controlled, multicenter, phase III recruited patients age 18 years or older with histologically confirmed cholangiocarcinoma muscle-invasive gallbladder after resection curative intent an Eastern Cooperative Oncology Group performance...
Epstein-Barr virus (EBV) is associated with several malignancies including nasopharyngeal carcinoma, a high incidence tumor in Chinese populations, which cells express the two EBV antigens EB nuclear antigen 1 (EBNA1) and latent membrane protein 2 (LMP2). Here, we report phase I trial of recombinant vaccinia virus, MVA-EL, encodes an EBNA1/LMP2 fusion designed to boost T-cell immunity these antigens. The vaccine was delivered Hong Kong patients carcinoma determine safe immunogenic dose....
Results of small-scale studies have suggested that stem-cell therapy is safe and effective in patients with liver cirrhosis, but no adequately powered randomised controlled trials been done. We assessed the safety efficacy granulocyte colony-stimulating factor (G-CSF) haemopoietic infusions cirrhosis.